Lexicon Pharmaceuticals LXRX Business Segments — Interest income and other
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Lexicon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lexicon Pharmaceuticals's business segments — interest income and other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lexicon Pharmaceuticals's business segments — interest income and other?
- Lexicon Pharmaceuticals (LXRX) reported business segments — interest income and other of $1.54M in Q1 2026.
- How has Lexicon Pharmaceuticals's business segments — interest income and other changed year-over-year?
- Lexicon Pharmaceuticals's business segments — interest income and other decreased by 30.5% year-over-year, from $2.22M to $1.54M.
- What is the long-term trend for Lexicon Pharmaceuticals's business segments — interest income and other?
- Over 3 years (2022 to 2025), Lexicon Pharmaceuticals's business segments — interest income and other has grown at a 63.0% compound annual growth rate (CAGR), from $1.6M to $6.91M.
- What does business segments — interest income and other mean?
- This metric represents the non-operating income generated by a specific business segment, primarily derived from cash equivalents, short-term investments, and other miscellaneous financial activities. It reflects the segment's ability to generate supplemental yield from its allocated capital base. Monitoring this helps investors assess the efficiency of cash management within the segment's operations.